Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15230043 | 0.82 | APAF1 (0.51) | ALDH1A1NPSR1APAF1GAAPOLQ | |
| SCHEMBL2066498 | 0.82 | GAA (0.67) | ALDH1A1NPSR1GAAPOLQSMN1; SMN2 | |
| SCHEMBL19321643 | 0.80 | NPSR1 (0.48) | ALDH1A1NPSR1APAF1GAAPOLQ | |
| SCHEMBL13066493 | 0.79 | ALDH1A1 (1.00) | ALDH1A1APAF1GAAPOLBMAPT | |
| SCHEMBL4744968 | 0.77 | ALDH1A1 (0.69) | ALDH1A1APAF1GAAPOLBMAPT | |
| SCHEMBL11832157 | 0.75 | NPSR1 (0.43) | ALDH1A1NPSR1APAF1GAAPOLQ | |
| SCHEMBL17382011 | 0.74 | ALDH1A1 (0.65) | ALDH1A1APAF1GAAPOLBMAPT | |
| SCHEMBL26944228 | 0.71 | ALDH1A1 (0.61) | ALDH1A1APAF1GAASMN1; SMN2POLB | |
| SCHEMBL21960820 | 0.70 | NPSR1 (0.49) | ALDH1A1NPSR1APAF1GAASMN1; SMN2 | |
| SCHEMBL2067893 | 0.69 | NPSR1 (0.44) | ALDH1A1NPSR1GAAPOLQSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157929-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | ARES TRADING SA (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| WO-2015196759-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | ALDH1A1 4598/4885NPSR1 358/4885APAF1 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.